Figure 3. Risk of 14 Cancers in Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) Compared With Patients Not Receiving GLP-1RAs.
IR indicates incidence rate.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.